Methodology of patient care for elevated PSA after prostate cancer treatment: A primary care perspective

References

• Prostate Cancer Overview. American Cancer Society. 2015. Available from http://www.cancer.org/cancer/prostatecancer/overviewguide/prostate-cancer-overview-key-statistics. [Last accessed 1 January 2015]
   Google Scholar
• Ebell MH. Predicting the risk of recurrence after surgery for prostate cancer. Am Fam Physician 2005;72:2511–12
   PubMed Web of Science ®Google Scholar
• Cancer Control After Radical Prostatectomy. Johns Hopkins Medicine. 1997. 6. Available from http://urology.jhu.edu/newsletter/prostate_cancer43.php
   Google Scholar
• Bong GW, Keane TE. Salvage options for biochemical recurrence after primary therapy for prostate cancer. Can J Urol 2007;14:2–9
   PubMedGoogle Scholar
• Thompson IM, Valicenti R, Albertsen PC, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy. J Urol 2013;190:441–9
   PubMed Web of Science ®Google Scholar
• PSA Rising Post-Treatment. Prostate Cancer Foundation. Available from http://www.pcf.org/site/c.leJRIROrEpH/b.5838551/k.6D69/PSA_Rising_PostTreatment.htm
   Google Scholar
• Anderson CB, Penson DF, Ni S, Makarov DV, Barocas DA, et al. Centralization of Radical Prostatectomy in the United States. J Urol 2013;189:500–6
   PubMed Web of Science ®Google Scholar
• Stephenson AJ, Scardino PT, Eastham JA, Bianco FJJr, Dotan ZA, DiBlasio CJ, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005;23:7005–12
   PubMed Web of Science ®Google Scholar
• Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF3rd, Skoglund S, et al. 15-year biochemical relapse free survival in clinical stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; seattle experience. Int J Radiat Oncol Biol Phys 2007;67:57–64
   PubMed Web of Science ®Google Scholar
• Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G, et al. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial. Eur Urol 2009;55:422–30
   PubMed Web of Science ®Google Scholar
• Lee BH, Kibel AS, Ciezki JP, Klein EA, Reddy CA, Yu C, et al. Are biochemical recurrence outcomes similar after radical prostatectomy and radiation therapy? Analysis of prostate cancer-specific mortality by nomogram-predicted risks of biochemical recurrence. Eur Urol 2015;67:204–9
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hematol Oncol 2013;11:14–23
   PubMedGoogle Scholar
• What Happens if PSA Comes Back After Surgery. Johns Hopkins Medicine. 2000. 5. Available from http://urology.jhu.edu/newsletter/prostate_cancer52.php
   Google Scholar
• Stock RG, Stone NN, Cesaretti JA. Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. Int J Radiat Oncol Biol Phys 2003;56:448–53
   PubMed Web of Science ®Google Scholar
• Macdonald OK, D’Amico AV, Sadetsky N, Shrieve DC, Carroll PR, et al. Adjuvant radiotherapy in prostate cancer: predictors of prostate-specific antigen recurrence from the CaPSURE database. Urology 2007;70:106–10
   PubMed Web of Science ®Google Scholar
• Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467–79
   PubMed Web of Science ®Google Scholar
• Gomez P, Manoharan M, Kim SS, Soloway MS, et al. Radionuclide bone scintigraphy in patients with biochemical recurrence after radical prostatectomy: When is it indicated? BJU Int 2004;94:299–302
   PubMed Web of Science ®Google Scholar
• Novel treatments for recurrent prostate cancer. Mayo Clinic. Available from http://www.mayoclinic.org/medical-professionals/clinical-updates/general-medical/novel-treatments-for-recurrent-prostate-cancer
   Google Scholar
• Lowe VJ, Kwon ED. PET in prostate cancer: A focus on C-11 choline. Mol Imaging Biol 2015;5:1–7
   Google Scholar
• Rinnab L, Simon J, Hautmann RE, Cronauer MV, Hohl K, Buck AK, et al. [11C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009;27:619–25
   PubMed Web of Science ®Google Scholar
• Punnen S, Cooperberg MR, D’Amico AV, Karakiewicz PI, Moul JW, Scher HI, et al. Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 2013;64:905–15
   PubMed Web of Science ®Google Scholar
• Sciarra A, Barentsz J, Bjartell A, Eastham J, Hricak H, Panebianco V, Witjes JA, et al. Advances in magnetic resonance imaging: how they are changing the management of prostate cancer. Eur Urol 2011;59:962–77
   PubMed Web of Science ®Google Scholar
• Wu LM, Xu JR, Gu HY, Hua J, Zhu J, Chen J, et al. Role of magnetic resonance imaging in the detection of local prostate cancer recurrence after external beam radiotherapy and radical prostatectomy. Clin Oncol 2013;25:252–64
   Web of Science ®Google Scholar
• Wadia R, Petrylak DP. New developments in the treatment of castration resistant prostate cancer. Asian J Androl 2014;16:555–60
   PubMed Web of Science ®Google Scholar
• Thomas CT, Bradshaw PT, Pollock BH, Montie JE, Taylor JM, Thames HD, et al. Indium-111-capromab pendetide radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy. J Clin Oncol 2003;21:1715–21
   PubMed Web of Science ®Google Scholar
• Finley DS, Belldegrun AS. Salvage cryotherapy for radiation-recurrent prostate cancer: outcomes and complications. Curr Urol Rep 2011;12:209–15
   PubMedGoogle Scholar
• Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, et al. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011;60:205–10
   PubMed Web of Science ®Google Scholar
• Pickles T, Steinhoff G. Surgical orchiectomy: Time to revisit. BCMJ 2003;45:216–17
   Google Scholar
• Gomella LG. Effective testosterone suppression for prostate cancer: is there a best castration therapy? Rev Urol 2009;11:52–60
   PubMedGoogle Scholar
• Sartor O. Eligard: leuprolide acetate in a novel sustained-release delivery system. Urology 2003;61:25–31
   PubMed Web of Science ®Google Scholar
• Van Poppel H, Klotz L. Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol 2012;19:594–601
   PubMed Web of Science ®Google Scholar
• Van Poppel H. Evaluation of degarelix in the management of prostate cancer. Cancer Manag Res 2010;2:39–52
   PubMedGoogle Scholar
• Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371:424–33
   PubMed Web of Science ®Google Scholar
• Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol 2005;7:S37–43
   PubMedGoogle Scholar